plodicitinib (DWP212525) / Daewoong Pharma - LARVOL DELTA

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DWP212525, an Oral Small-Molecule Inhibitor Targeting JAK and Tec Family Kinases, after Single-Dose in Healthy Adults Volunteers. (ACR Convergence 2026) - No abstract available

Clinical • PK/PD data • Inflammation

Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Trial completion date: Jun 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Immunology

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.

New P1 trial • Immunology

Daewoong Pharmaceutical, new drug for autoimmune disease treatment 'DWP212525' enters clinical trial [Google translation] (Health Korea News) - "Daewoong Pharmaceutical received approval for the Phase 1 clinical trial plan (IND) for 'DWP212525' from the Ministry of Food and Drug Safety on the 25th. The test is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of 'DWP212525' on healthy adult male volunteers. The clinical institution is Seoul National University Hospital."

New P1 trial • Atopic Dermatitis • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis